Deramiocel (CAP-1002)

Duchenne muscular dystrophy

Manufacturer: Capricor Therapeutics
Regulatory submission: Class 2 BLA resubmission submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Pharmacology

4 evidence topics · 6 sources